Compare GSK plc (GSK) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Zillow Group Inc Class C — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: GSK plc is far larger — about 13.9× Zillow Group Inc Class C's market cap, and GSK plc pays a 3.9% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Zillow Group Inc Class C for 38 Days on average.
| GSK | Z | |
|---|---|---|
Market Cap | $91.88B | $6.59B |
Volume | 7,730,529 | 9,134,294 |
Sector | Health | Media |
52-Week High | $61.18 | $78.04 |
52-Week Low | $43.24 | $27.13 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $111.88B | $6.47B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Zillow Group (Z) trades at $29.17, up 6.93% in the past 24 hours, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, and net income turning positive at $23M after a $112M loss the prior year. Recent earnings show two consecutive beats, with Q2 2026 EPS of $0.52 exceeding expectations of $0.4459. Analyst consensus remains divided with a $60.33 price target representing significant upside potential from current levels.
The outlook for Zillow appears cautiously optimistic with improving profitability and strategic AI integration, though the stock faces headwinds from high mortgage rates and housing market volatility. The company's transition to an integrated transaction platform shows promise, but execution risks remain amid competitive pressures and regulatory scrutiny. With a P/E ratio of 126.83 indicating premium valuation, investors should monitor housing market trends and the company's ability to sustain recent earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
